Linaclotide Patent Expiration
Linaclotide is Used for treating chronic idiopathic constipation, irritable bowel syndrome with constipation in adults, and functional constipation in pediatric patients. It was first introduced by Abbvie Inc
Linaclotide Patents
Given below is the list of patents protecting Linaclotide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Linzess | US10675325 | Stable formulations of linaclotide | Aug 11, 2031 | Abbvie |
| Linzess | US10702576 | Stable formulations of linaclotide | Aug 11, 2031 | Abbvie |
| Linzess | US7304036 | Methods and compositions for the treatment of gastrointestinal disorders | Aug 30, 2026 | Abbvie |
| Linzess | US7371727 | Methods and compositions for the treatment of gastrointestinal disorders |
Jan 28, 2024
(Expired) | Abbvie |
| Linzess | US7704947 | Methods and compositions for the treatment of gastrointestinal disorders |
Jan 28, 2024
(Expired) | Abbvie |
| Linzess | US7745409 | Methods and compositions for the treatment of gastrointestinal disorders |
Jan 28, 2024
(Expired) | Abbvie |
| Linzess | US8080526 | Methods and compositions for the treatment of gastrointestinal disorders |
Jan 28, 2024
(Expired) | Abbvie |
| Linzess | US8110553 | Methods and compositions for the treatment of gastrointestinal disorders |
Jan 28, 2024
(Expired) | Abbvie |
| Linzess | US8748573 | Formulations comprising linaclotide | Oct 30, 2031 | Abbvie |
| Linzess | US8802628 | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration | Oct 30, 2031 | Abbvie |
| Linzess | US8933030 | Treatments for gastrointestinal disorders | Feb 17, 2031 | Abbvie |
| Linzess | US9708371 | Treatments for gastrointestinal disorders | Aug 16, 2033 | Abbvie |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Linaclotide Generics
Several generic applications have been filed for Linaclotide. The first generic version for Linaclotide was by Mylan Pharmaceuticals Inc and was approved on Feb 9, 2021. And the latest generic version is by Aurobindo Pharma Ltd and was approved on Feb 7, 2023.
Given below is the list of companies who have filed for Linaclotide generic.
1. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Linaclotide. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 145MCG | capsule | Discontinued | ORAL | N/A | Feb 7, 2023 |
| 290MCG | capsule | Discontinued | ORAL | N/A | Feb 7, 2023 |
2. MYLAN
Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Linaclotide. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 145MCG | capsule | Discontinued | ORAL | N/A | Feb 9, 2021 |
| 290MCG | capsule | Discontinued | ORAL | N/A | Feb 9, 2021 |